About me
I am Ayan Sengupta, co-founder and CEO of MyImmune, where we teach machines to read the immune system. From a small blood sample we sequence a person’s T-cell and B-cell receptors and use AI to turn that repertoire into earlier diagnoses, better predictions of who will respond to a therapy, and fully human antibodies discovered entirely in silico. I came to immunology by way of control theory at IIT Bombay, reinforcement learning research at NEC, and building AI products at Tokyo startups, and I still enjoy the moment when a hard biological question becomes a tractable machine learning problem. I live in Tokyo, mentor engineers and founders on MentorCruise, and you can reach me at ayan.sengupta@myimmune.ai.
2024 - Present
Co-founder and Chief Executive Officer (CEO) of MyImmune, an Osaka University spin-out building an AI platform that deciphers the adaptive immune system from a single blood sample. I co-founded the company in June 2024 with Prof. Daron Standley (Osaka University) and Dr. Florian Hauer, served as CTO building the core AI and engineering stack, and took over as CEO in June 2026.
MyImmune translates adaptive immune receptor repertoires (T-cell and B-cell receptor sequences) into biomarkers for diagnostics, predicts patient responses to cancer and autoimmune therapies, and runs AbSapien, an in silico antibody discovery platform that retrieves fully natural human antibodies instead of engineering them from animal-derived sources.
Company milestones
- [Sep 2026] Selected for the OIST Innovation Accelerator Program in Okinawa, where I am an Accelerator Fellow at the Okinawa Institute of Science and Technology.
- [Jul 2026] Presented AbSapien at KOZAROCKS 2026, Okinawa.
- [Jul 2025] Joined the inaugural cohort of the Clinical Incubator at Charité (CLIC), Berlin Institute of Health.
- [Dec 2024] Presented at the Osaka University DeepTech Showcase, Japan Innovation Campus, Palo Alto.
- [Oct 2024] Closed a pre-seed round led by Osaka University Venture Capital (OUVC). Press release
In the news
- Is AI the future of cancer treatment? Startup MyImmune thinks so - FlotBio with Philip Hemme (video)
- Four deep-tech startups selected from around the world begin new ventures in Okinawa - OIST News, Sep 2026
- Global Deep-Tech Startups Launch Ventures in Okinawa - Mirage News, Sep 2026
- OUVC Invested in MyImmune Corporation - OUVC, Oct 2024
Publications from this work
- Wang S, Sengupta A, Li S, Standley DM. A germline shortcut in protein language model retrieval of adaptive immune receptors. bioRxiv, 2026.
- Biró B, Llamas-Covarrubias MA, Sengupta A, Standley DM. Stratification of immunotherapy responses by adaptive immune receptor repertoires. Trends in Molecular Medicine 32(8):761-777, 2026.
- Jiravejchakul N, Sengupta A, Li S, Upadhyaya D, Llamas-Covarrubias MA, Hauer F, Haruna S, Standley DM. Accurate and scalable multi-disease classification from adaptive immune repertoires. bioRxiv, 2025.
- Xu Z, Ismanto HS, Saputri DS, Haruna S, Sun G, Wilamowski J, Teraguchi S, Sengupta A, Li S, Standley DM. Robust detection of infectious disease, autoimmunity, and cancer from the paratope networks of adaptive immune receptors. Briefings in Bioinformatics 25(5), 2024.
Full list on Google Scholar.
2023-2024
I contributed to an AI startup, Incubit in Tokyo focused on enhancing productivity through innovative AI solutions. I led the development of Tektome, an LLM-driven architectural design tool that transforms raw design data from BIM, CAD, and architectural diagrams into structured, actionable insights. By automating and refining data pipelines, Tektome empowers architects and designers with a robust, tailored database for streamlined workflows.
2022 - 2023
I was part of the Machine Learning team at an AI startup Cogent Labs, whose primary goal is to power productivity with Artificial Intelligence. Cogent Labs has been in the list of LinkedIn Top Startups 2021 for the three consecutive years. My work was majorly focused in one of our top products called SmartRead.
To get a brief idea on our product, have a glance at the following video:
2019 - 2022
I was working in the Global Innovation Unit of NEC Corporation, Japan as an AI researcher. I was responsible for extending the boundaries of research in the field of Automated Negotiation. My work fell under the intersection of domains of Automated Negotiation, Reinforcement Learning, and Deep Learning.
Moreover, I’m also a member of the group of experts of the United Nations Centre for Trade Facilitation and Electronic Business (UN/CEFACT). I actively participate in the public debate for the disclosure and sustainable development of technology.
To know more about my work at NEC, checkout the following links:
- Negotiation Automation Platform
- UNECE E-Negotiation Project
- Automated Negotiation SCM Consortium (Japanese)
- BIRD Initiative
- Automated Negotiating Agents Competition
- Press Release by IIC Aug, 2019
- Press Release by NEC Aug, 2019
- Press Release Jan, 2022
2016 - 2019
Previously I worked as Research Assistant in Control and Computing lab in IIT Bombay. I majorly worked on novel algebraic solvers for solving boundary control problems of real-world applications governed by partial differential equations. During that time, I also completed my Masters in Control and Computing from the Indian Institute of Technology Bombay. My major interests are in the domain of data science, machine learning, deep learning, and reinforcement learning.
Recent accomplishments:
- [2026] Appointed CEO of MyImmune (Jun 2026); selected for the OIST Innovation Accelerator Program (Sep 2026)
- [2026] Publication: bioRxiv: A germline shortcut in protein language model retrieval of adaptive immune receptors
- [2026] Publication: Trends in Molecular Medicine: Stratification of immunotherapy responses by adaptive immune receptor repertoires
- [2025] Publication: bioRxiv: Accurate and scalable multi-disease classification from adaptive immune repertoires
- [2025] MyImmune joins the inaugural cohort of the Clinical Incubator at Charité (CLIC), Berlin
- [2024] Co-founded MyImmune; pre-seed round led by Osaka University Venture Capital
- [2024] Publication: Briefings in Bioinformatics: Robust detection of infectious disease, autoimmunity, and cancer from the paratope networks of adaptive immune receptors
- [2022] Publication: IJCAI 2022: Transfer Learning Based Adaptive Automated Negotiating Agent Framework
- [2022] Competition: Japan Embassy Online Photo Competition
- [2021] Publication: AAMAS 2021: An Autonomous Negotiating Agent Framework with Reinforcement Learning based Strategies and Adaptive Strategy Switching Mechanism
- [2020] Competition: ANAC 2020
For more projects check out my GitHub page.
